Mid-April saw the opening of a new Abbott Laboratories biologics manufacturing facility in Puerto Rico to support the long-term supply of its leading biologic agent Humira as well as other future biologics.
Sciele Pharma Inc. recently reached an agreement to acquire Alliant Pharmaceuticals Inc., a privately held pediatric specialty pharmaceutical company headquartered in Alpharetta, Ga., in a deal under which Sciele will pay $122 million in cash. In turn, Alliant Pharmaceuticals is expected to generate revenues of approximately $50 million to $60 million for the full-year 2007 for Sciele.
INC Research, a therapeutically focused contract research organization (CRO), recently announced the strategic acquisition of Advanced Biologics to strengthen its infectious disease practice. Advanced Biologics is a full-service CRO specializing in full-service clinical development to the pharmaceutical and biotechnology industries worldwide.
Cognia, a database specialist for the pharmaceutical and biotechnology industries, has announced its plans to create a new operations center in Edinburgh. The new center will be responsible for commercializing and deploying text mining systems that help PhD-level curators analyze large quantities of scientific text to identify and extract valuable information.
Looking to expand its European Union market presence and strengthen its brand identity, Phenomenex Inc. is acquiring what it calls two “successful, customer-focused distributors in chromatography consumables”: Bologna, Italy-based Chemtek Analytica S.R.L., a subsidiary of Labservice Analytica S.R.L., and privatelyheld SupWare, headquartered in Hilleroed, Denmark. Financial terms were not disclosed.
As it announces work on a restructuring plan, Avanir Pharmaceuticals is also announcing that it is ending relationships with two big pharma companies, AstraZeneca and Novartis—a direction that runs counter to what many perceive as the path to success for small- and mid-size biotech companies.
BrainCells Inc. announced in late March a research collaboration with H. Lundbeck A/S under which BrainCells is screening central nervous system targets and compounds from Lundbeck’s library using its neurogenesis-based technology.
In a three-year, 3 million Euro deal, life sciences knowledge solutions provider BIOBASE will coordinate a European Union research contract to develop innovative technology to analyze complex disease mechanisms.